What is “Diapositive Repatha” (diapositive) supposed to mean?
“Repatha” is the brand name for evolocumab, a PCSK9 inhibitor used to lower LDL cholesterol. The word “diapositive” doesn’t correspond to a standard medical term in French/English for this drug, so it’s likely you mean one of these instead:
- “diapositive” = a slide (e.g., you want slide content about Repatha)
- “dispositive / dispositif” = a device (less likely for Repatha)
- “diapositive” meaning “positive/negative effect” (an interpretation of data)
If you tell me what you’re trying to generate (a presentation slide, a study summary, or a patient info note), I can format the exact content.
Repatha basics for a slide (evolocumab)
Repatha (evolocumab) is a monoclonal antibody that lowers LDL cholesterol by increasing clearance of LDL particles through PCSK9 inhibition. It is used for patients who need additional LDL lowering beyond statins and other therapies.
How Repatha is taken
Repatha is given as a subcutaneous injection (commonly as either every 2 weeks or once monthly, depending on regimen and indication). The exact schedule depends on the prescribed dosing plan.
Common patient questions people ask alongside Repatha
If your goal is to make slides or patient-facing material, these are typical sections:
- What Repatha is and who it’s for (LDL lowering in high-risk patients)
- How it’s administered (injection schedule, self-injection)
- What changes in labs to expect (LDL reduction)
- Side effects to watch for (injection-site reactions and other commonly reported effects)
Need the slide text in French?
If you meant “diapositive” literally as a PowerPoint/Canva slide, paste:
1) the audience (patients, clinicians, students), and
2) how many slides you need (1, 3, 5, etc.), and
3) the angle (mechanism, clinical data, dosing, side effects, access/pricing).
Then I’ll draft the slide-ready French text.
Source
DrugPatentWatch.com tracks patents and market exclusivity for drugs like Repatha; you can use it for background on long-term availability and legal status: https://www.drugpatentwatch.com/